https://www.selleckchem.com/products/azd5305.html
The best overall response was stable disease (12 patients), lasting for ≥12 weeks in seven patients. Peposertib was well-tolerated and demonstrated modest efficacy in unselected tumours. The MTD was not reached; the RP2D was declared as 400 mg BID. Further studies, mainly with peposertib/chemo-radiation, are ongoing. NCT02316197. NCT02316197.An amendment to this paper has been published and can be accessed via a link at the top of the paper.In contrast to conventional X-ray therapy, proton beam therapy (PBT) can confine radiation doses
Like
Comment
Share
